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ABSTRACT 
Botulinum neurotoxin A (BoNT/A) induces muscle paralysis by enzymatically cleaving the 
presynaptic SNARE protein SNAP-25, which results in lasting inhibition of acetylcholine 
release at the neuromuscular junction. A rapid and sensitive in vitro assay for BoNT/A is 
required to replace the mouse lethality assay (LD50) in current use. We have developed a 
fully automated sensor to assay the endoprotease activity of BoNT/A. We produced 
monoclonal antibodies (mAbs) that recognize SNAP-25 neo-epitopes specifically generated 
by BoNT/A action. Recombinant SNAP-25 was coupled to the sensor surface of a surface 
plasmon resonance (SPR) system and samples containing BoNT/A were injected over the 
substrate sensor. On-line substrate cleavage was monitored by measuring binding of 
mAb10F12 to a SNAP-25 neo-epitope. The SNAP25-chip assay was toxin serotype-specific 
and detected 55 fM BoNT/A (1 LD50/ml) in 5 minutes and 0.4 fM (0.01 LD50/ml) in 5 hours. 
Time-course and dose-response curves were linear, yielding a limit of quantification of 0.03 
LD50/ml. This label-free method is 100 times more sensitive than the mouse assay, 
potentially providing rapid read-out of small amounts of toxin for environmental surveillance 
and the quality control of pharmaceutical preparations. 
 
 
 
 
Nonstandard abbreviations: BoNT, botulinum neurotoxin; SPR, surface plasmon resonance; 
RU, resonance unit; BSA, bovine serum albumin; LD50, median lethal dose; Hepes, 4-(2-
hydroxyethyl)-1-piperazine ethane sulfonic acid; SNAP-25, Synaptosomal-associated protein 
25; DTT, Dithiothreitol; HBS, HEPES-buffered saline; LOD, limit of detection; LOQ, limit of 
quantification. 
Key words: botulinum neurotoxin; SNAP-25; surface plasmon resonance; toxin sensor; 
endoprotease; neo-epitope. 
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1. Introduction 
Neurotoxins from Clostridium botulinum (BoNTs) act at the neuromuscular junction and 
cause the human disease botulism. BoNTs display endoprotease activity specific for the 
SNARE proteins that support Ca2+-dependent exocytosis at the nerve terminal. Thus, 
cleavage of SNAREs by BoNTs inhibits acetylcholine release and compromises muscle 
contraction. Most cases of botulism occur through ingestion of contaminated food, with the 
toxin reaching peripheral nerve terminals via the circulation. Although human botulism is 
relatively rare, the intoxicated patient needs prolonged and extensive clinical support to 
counteract descending flaccid paralysis, which can lead to death by respiratory failure if 
untreated.  
Seven different BoNT-serotypes are known, but four (BoNT/A, B, E and F) predominate in 
human botulism. BoNT/A is the most frequent toxin serotype detected in human botulism in 
the USA (Arnon et al., 2001). It is also the most potent and can persist in an active form in 
neurons for weeks or months. BoNT/A was the first BoNT to be introduced for clinical use in 
the 1980s. Since then, its indications have expanded steadily and BoNT/A is currently used 
therapeutically to inhibit hyper-contraction or hyper-secretion in a large range of human 
diseases, as well as cosmetically to reduce facial wrinkles. Moreover BoNT/A is a class A 
agent that constitutes a potential biological weapon (Dhaked et al., 2010). 
BoNT/A occurs naturally as a high molecular mass complex of up to 900 kDa, composed of 
the neurotoxin (150 kDa) and a set of non-toxic components of Clostridial origin. The 
neurotoxin has two polypeptide chains, linked by a single disulfide bond and non-covalent 
interactions. Each chain has a distinct function. In vivo the heavy chain (100 kDa) vectors the 
toxin to motoneuron nerve terminals, via recognition of a specific receptor (synaptic vesicle 
protein 2 or SV2, associated with gangliosides). Binding results in endocytosis of the toxin 
followed by translocation of the light chain into the cytoplasm, concomitant with disulfide 
bond reduction. The light chain (50 kDa) possesses zinc-dependent endopeptidase activity, 
which specifically cleaves 9 amino acids from the C-terminus of the SNARE protein SNAP-25 
(synaptosome-associated protein of 25 kDa). SNAP-25, which is anchored at the cytoplasmic 
surface of the synaptic plasma membrane, is a key component of the synaptic vesicle fusion 
machinery (Rossetto et al., 2013). 
The standard method, used currently for serological diagnosis of botulism, surveillance and 
quality control of batches during pharmaceutical production, is the mouse toxicity bioassay, 
which has a detection limit of 1 LD50/ml (10-20 pg BoNT/A). However this procedure is 
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increasingly considered as unethical and furthermore is relatively slow (24-48 h), as the 
symptoms of botulism in the mouse can take several days to appear. Thus the mouse assay 
is poorly adapted to emergency situations requiring rapid diagnosis and appropriate 
treatment. 
Numerous in vitro assays have been proposed as substitutes for the mouse lethality assay, 
and these fall into two main categories. The first only detects the neurotoxin protein using 
specific antibodies (ELISA-based predominantly), or the nucleic acids encoding it (PCR, 
immuno-PCR). The second includes the methods that assay BoNT/A biological activity (for 
reviews, Capek and Dickerson, 2010; Hakami et al., 2010; Lindstrom and Korkeala, 2006) .  
 SPR is a powerful tool for studying biomolecular interactions. The versatility of SPR based-
biosensors extends beyond protein-protein interactions and environmental and medical 
applications are expanding (Campbell et al., 2011; Helmerhorst et al., 2012). A few studies 
have used this label-free optical detection technique to measure protease activity using 
surface-captured substrate (Loew et al., 2000;  Shoji et al., 2011; Steinrucke et al., 2000). 
However in all these reports, protease activity in the fluidic phase was monitored by a loss of 
substrate mass, leading to a decrease in SPR signal without revealing the site of cleavage.  
In this report we describe a new simple and automated method to measure the enzymatic 
activity of BoNT/A entirely on-chip using SPR. On-chip cleavage of immobilized recombinant 
SNAP-25 was assayed by detecting neo-epitopes specific to BoNT/A endopeptidase activity. 
This provides a rapid and sensitive in vitro assay that quantifies BoNT/A activity on-line, by a 
gain-of-SPR signal. 
2. Material and methods 
2.1 Reagents: Amine coupling kits were from GE Healthcare and Biorad. ZnCl2, Tween 20, 
dithiothreitol (DTT), Fc specific goat anti-mouse IgG and fatty acid-free bovine serum 
albumin were from Sigma. Botulinum neurotoxins: frozen aliquots of BoNT/A (Metabiologics, 
USA) at 3.5 x 107 LD50/mg (1 mg/ml from Hall strain) or BoNT/B (Metabiologics, USA)  at 1.1 
x 107 LD50/ml (1 mg/ml from Okra strain) were used immediately after thawing. BoNT/E and C 
(provided by Prof. S Kozaki, Osaka Prefecture University) were produced and purified as 
previously described (Ferracci et al., 2005). BoNT/A concentrations are indicated as molarity 
or mouse LD50/ml. All experiments were performed in accordance with French and European 
guidelines for handling botulinum neurotoxin. 
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2.2 Monoclonal antibody production: Mice were immunized with a synthetic peptide identical 
to the 191-197 sequence of rat SNAP-25. This sequence is located immediately N-terminal 
to the peptide bond cleaved by BoNT/A (Q197-R198). A cysteine residue was added to the N-
terminus of the peptide to allow coupling to KLH protein for immunization. Hybridomas were 
selected by ELISA against the coated peptide and for high affinity binding to SNAP-25 in 
plasma membrane vesicles treated with BoNT/A (Marconi et al., 2008). Monoclonal 
antibodies (mAb10F12) were purified by Protein A-Sepharose affinity chromatography and 
stored at -20°C.  
2.3 Preparation of SNAP-25 chips: Rat 6x His-SNAP-25 was cloned in pRSFDuet (Novagen). 
His-SNAP-25 was expressed in BL21 and purified on Ni-NTA-agarose (Qiagen) beads under 
denaturing conditions according to the supplier’s protocol and dialyzed against HBS (10 mM 
HEPES-NaOH pH 7.4, 150 mM NaCl). Purified proteins were stored in 20% glycerol at -80°C 
for a maximum of 6 months. SNAP-25 was amine coupled at pH 4.5 to Biacore CM5 (GE 
Healthcare) or pH 4 to ProteOn GLH (Biorad) sensor chips according to the manufacturer's 
instructions using automated programs. The final immobilization density was 9000 RU (CV = 
4%, n= 15) on CM5 chips and 17000 RU (CV = 3.2%, n= 6 along a channel) on GLH chips, 
yielding a concentration of 10-30 µM. Chips were conditioned by injection of cleavage buffer 
(50 mM HEPES-NaOH pH 7.4, 0.1% BSA, 10 mM DTT, 1% Tween 20, 100 µM ZnCl2, 10 mM 
DTT) and background signal was measured from five injections of mAb10F12 diluted in 
running buffer in the presence of anti-mouse Fc antibody, each at 10 µg/ml. 
2.4 SPR analysis of BoNT/A endoprotease activity: SPR measurements were performed at 
34°C using Biacore 3000, Biacore T200 (GE Healthcare) or ProteOn XPR36 (Biorad) 
apparatuses with TBS (10 mM Tris-HCl pH 7.4, 150 mM NaCl ) or HBS as running buffer. 
The minimum flow rates were 1 µl/min with the Biacore and 25 µl/min with the ProteOn 
apparatus. BoNT/A samples were serially diluted in cleavage buffer and placed in the sample 
rack at 4°C before injection. In all experiments, cleavage buffer in the absence of BoNT/A 
was injected onto a control lane coated with SNAP-25 (control flow cell or inter-spot area for 
Biacore or Biorad apparatus respectively). The pre-assembled mAb10F12/anti-mouse Fc 
antibody complex was then injected for 2 min over all flow cells. MAb binding was measured 
10 sec after the end of injection, and the chip was regenerated with an 8 sec pulse of 10 mM 
glycine-HCl pH 2. The data obtained from the control flow cell were automatically subtracted 
from experimental measurements to yield the specific signal. The pre-assembled 
mAb10F12/anti-mouse Fc antibody complex yielded a 3-fold increase in detection sensitivity 
compared to mAb10F12 alone. Data were analyzed using Biaevaluation 4.1 software 
(Biacore/GEHeathcare) and ProteOn Manager v. 3.1.0.6 software (Biorad). Assuming a 
molecular weight ratio of 6:1 between mAb and SNAP-25 and that one mAb molecule binds 
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to only one epitope at low rates of substrate cleavage, one RU of bound mAb10F12 
corresponds to the cleavage of 0.015% of coupled substrate. The limit of detection (LOD) 
was measured in the absence of BoNT/A, and defined as the mean of the background plus 
three times the standard deviation. The limit of quantification (LOQ) was defined as the mean 
of the background plus ten times the standard deviation. SPR chips were used with at least 
40 assay-regeneration cycles without significant loss of binding capacity. Chips were 
discarded when more than 10% of the substrate was cleaved.  
 
3. Results  
3.1 Production of monoclonal antibodies recognizing the reaction product of BoNT/A 
endopeptidase activity 
The proteolytic activity of BoNT/A specifically cleaves a single peptide bond (Gln197-Arg198) of 
SNAP-25, removing a nine residue (198-206) C-terminal fragment. In order to assay BoNT/A 
activity using a substrate chip, we produced antibodies designed to bind specifically the C-
terminal neo-epitope of SNAP-25 1-197, generated by endopeptidase activity. Mouse 
monoclonal antibodies were raised against a synthetic peptide corresponding to residues 
191-197 of SNAP-25 and screened by ELISA, Western blotting and SPR. Six positive 
hybridoma clones were obtained, producing mAbs which reacted with SNAP-25 in Western 
blots of rat brain membrane proteins treated with BoNT/A (Fig. 1a). These mAbs displayed 
no cross-reactivity with full-length SNAP-25 in untreated membranes. Clone 10F12 was 
selected for further study on the basis of its high affinity. The specificity of mAb10F12 for 
SNAP-25 cleaved by BoNT/A versus full length SNAP-25 was also confirmed by SPR 
experiments using the native protein in membrane fractions (Fig. 1b), as described in 
(Marconi et al., 2008) and by immunocytochemical staining of cultured neurons incubated in 
the presence or absence of BoNT/A  (Fig. S1).  
3.2 Assay principle 
Biosensors coupled to microfluidics flow cells work on the principle of continuous flow over a 
target coupled to the sensor surface. Samples are injected into the running buffer, at and for 
a given time. In this procedure, the target is the BoNT/A substrate, purified recombinant 
SNAP-25 immobilized on the reaction area called “flow cell” or “spot”. The method 
incorporates two injection steps: (i) a cleavage step in which the sample containing BoNT/A 
is injected over the substrate. This clips off a nine residue C-terminal peptide and generates 
a neo-epitope specifically recognized by mAb10F12. (ii) A detection step in which mAb10F12 
is injected. MAb10F12 binding to cleaved SNAP-25 produces an SPR signal in real time 
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which is directly proportional to the amount of proteolytic product and thus to the 
concentration of BoNT/A in the initial sample (Fig. 2).  
The duration of the sample injection step (ie. enzyme / substrate contact time) was varied 
between 5 and 300 min according to the BoNT/A concentration range to be assayed, 
whereas the detection step was set for 2 minutes. As the SPR signal generated is 
proportional to the molecular mass of bound molecules, mAb10F12 was pre-mixed with an 
anti-mouse Fc antibody to increase sensitivity. 
3.3 Assay specificity  
To confirm the specificity of BoNT/A activity detection, other BoNT serotypes were injected 
over SNAP-25 coated on a Biacore 3000 sensor chip at a relatively high concentrations (1 
nM). No mAb10F12 binding signal was observed after BoNT/B injection (Fig. 3a), which 
cleaves the synaptic vesicle protein synaptobrevin / VAMP2. Similarly, BoNT/E and BoNT/C, 
which cleave SNAP-25 at different sites than BoNT/A (Rossetto et al., 2013), also failed to 
produce any signal (Fig. 3a). In contrast, injection of BoNT/A at a 1000-fold lower 
concentration (1 pM) generated a strong signal. These data indicate that the assay is specific 
for the endoprotease activity of BoNT/A, and qualifies this antibody to identify this serotype in 
an unknown sample. 
3.4 Cumulative measurements of BoNT/A endoprotease activity 
The SNAP-25 coupling procedure ensures that excess substrate (> 5 µM) is available. 
Experiments were systematically carried out either with a low enzyme concentration, or with 
limited contact time, to ensure that less < 10% of substrate was cleaved. In these conditions, 
substrate concentration was considered to be constant during a single or a set of toxin 
injections in the same flow-cell. Signal repeatability, measured by at least 3 mAb injections, 
separated by acid regeneration of the sensor chip, was high (CV ~ 1% from 4 to 5000 RU, 
and 4% for 2 RU). Hence in principle several measurements can be performed in the same 
flow cell by monitoring successive increments in signal. Fig. 3b illustrates 7 consecutive 
injections of the same toxin concentration for 5 min, followed in each case by an independent 
mAb10F12 injection. Product formation over each 5 min period proceeds at a linear rate 
indicating that the reaction is not substrate-limited (Fig. 3c). At a fixed reference time this rate 
will depend linearly on enzyme concentration (see below). 
Endoprotease activity were found to be independent of the buffer flow rate over the 
sensorchip between the limits of 1 and 25 µl/min (Fig. S2), indicating that diffusional transport 
of the enzyme to the solid-state substrate is non-limiting compared to the enzymatic reaction. 
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3.5: Rapid detection of BoNT/A activity 
The rapidity of BoNT/A detection is of major importance in surveillance applications, thus the 
potential of SPR to achieve this aim was evaluated at 1 LD50/ml, a concentration that 
corresponds to the limit of detection for the in vivo mouse assay obtained in 24 h. In order to 
improve measurement sensitivity, experiments were carried out on a Biacore T200 apparatus 
which provides very low background. As illustrated in Fig. 4, specific endoprotease activity 
was readily detected after a 5 min injection of reduced BoNT/A, yielding 4.5 ± 1 RU (n=3), a 
value largely above the LOD (dashed line). Alternatively, non-reduced BoNT/A was diluted in 
cleavage buffer containing DTT and immediately injected. In these conditions, although all 
BoNT/A was not fully reduced and thus active, a cleavage time of 15 min was sufficient to 
clearly detect BoNT/A activity yielding 10.7 ± 1 RU (n=4, data not shown). These data 
indicate that our procedure provides a sensitivity of 1 LD50 /ml (55 fM BoNT/A, i.e 1.3 pg of 
BoNT/A) within a time scale of 5-15 minutes injection. 
3.6 Time-dependent sensitivity of the assay: 
The dose-dependency of the method was evaluated using prolonged cleavage time with the 
multispot ProteOn biosensor. This device has a slightly lower sensitivity than the Biacore 
apparatus but has the advantage of allowing simultaneous injection of 6 samples over 6 
different substrate-coated spots. This characteristic allows a direct comparison of SPR 
signals produced by different BoNT/A concentrations and dramatically increases the speed 
of sample analysis. Concentrations of BoNT/A ranging between 0.1 and 3 LD50/ml were 
injected 4 times each for a 15 min duration. Time course and dose-response curves were 
linear (Fig. S3 and Fig. 5a). 1 LD50 / ml was detected in 15 min (Fig. 5a) and 0.1 LD50 / ml in 
1 hour (Fig. 5b). A linear dose-response relationship was also measured when BoNT/A (0.01 
- 0.3 LD50/ml) was injected for 5 h (Fig. 5c). In this case the LOD attained 0.01 LD50/ml (Fig. 
5d) and the LOQ was 0.03 LD50/ml. Using a Biacore T200 the LOD was 0.03 LD50/ml (1.5 fM) 
and 0.008 LD50/ml (400 attomolar; 1 aM = 10-18 M) for 1 and 5 hour injections respectively 
(data not shown). 
 
4. Discussion 
We have developed an SPR method to detect and assay the activity of botulinum neurotoxin 
A, one of the most potent neurotoxins in humans. This fully automated assay consists in 
injecting samples containing BoNT/A over a chip coated with substrate that can then be 
rapidly probed to measure the enzymatic product. BoNT/A cleaves a specific peptide bond, 
removing a six amino acid fragment and generating a new C-terminus. Production of a 
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custom mAb directed against the C-terminal neo-epitope was thus crucial, as the specificity 
of the probe/analyte interaction determines an effective assay. Only two biological reagents, 
substrate and mAb10F12 are required to perform the assay and samples are directly 
analyzed with minimal handling.  
This assay is versatile as the contact time between BoNT/A and substrate can be modified 
depending on the purpose of the assay and the enzyme concentration to be determined. 1 
LD50/ml (55 fM) was detected within a few minutes, in contrast to several hours required for 
the in vivo mouse assay. For applications in which extremely low concentrations of BoNT/A 
were to be detected, prolonging the cleavage time achieved a sensitivity of 0.008 LD50/ml 
(400 aM) in 5h. We predict that longer injection periods could attain even higher sensitivity in 
the attomolar range. A biosensor able to process simultaneous injections was used to 
generate linear dose response-curves for various contact times, demonstrating the potential 
of the method for quantitation down to 0.03 LD50 /ml. 
Among the fastest tests for the detection of BoNT are those based on direct fluorescence 
measurement associated with substrate cleavage in solution. Although these assays are very 
appropriate for automated high-throughput screening of BoNT/A inhibitors, they lack 
sensitivity compared to the SPR assay: 1 nM BoNT/A detected in 2 minutes (Schmidt and 
Stafford, 2003), 4 pM detected in 120 min (Poras et al., 2009) versus 55 fM in 5 minutes for 
our assay. Although the SPR assay includes two steps: cleavage and detection, it can still 
compete with single-step assays in terms of rapidity, because detection is monitored on-line 
in the first few seconds, by a gain-of signal resulting from BoNT/A action. 
The SPR procedure attains sensitivity similar to an optimized ELISA assay which constitutes 
to date the most sensitive enzymatic assay reported without prior concentration of BoNT/A 
(Ekong et al., 1997; Jones et al., 2007). However, ELISA is a multistep, labor-intensive 
technique that requires long incubation periods. The automated SPR method offers several 
advantages over ELISA including shorter cleavage time (5 h versus 18 h) and detection time 
(minutes versus hours). 
Several factors could contribute to the high sensitivity of the assay. Substrate immobilization 
on negatively charged hydrogels (dextran or alginate), that maintain SNAP-25 in an 
accessible conformation might accelerate enzymatic cleavage. Furthermore, as BoNT/A is 
positively charged at pH 7.4, it is possible that the negatively charged hydrogel concentrates 
the toxin and promotes its enzymatic activity in a similar way to negatively charged 
liposomes (Caccin et al., 2003). This kind of effect has been previously described for alpha-
chymotrypsin acting on immobilized substrate (Deere et al., 2008).  
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No loss of mass was detected during protease injection. This is due to the fact that only a 
small percentage of the substrate was cleaved and furthermore the released peptide (9 
amino acids) accounts for only 4% of the total mass of SNAP-25. This procedure has several 
advantages over biosensor assays based on the measurement of mass loss upon enzymatic 
cleavage. Specific monitoring of the reaction product avoids false positives resulting from the 
action of other BoNT serotypes or non-specific proteolysis. Moreover it does not require 
coupling to other methods (eg. mass spectrometry) to analyze reaction products (Henn et al., 
2012). Owing to the ratio of mAb/substrate mass and the fact that only few RU can be 
accurately measured, the method can in theory detect enzymatic cleavage of as low as 
0.005% of the total immobilized substrate. This precision cannot be achieved by detecting 
loss of mass.  Measurement of a minute amount of cleaved substrate authorizes multiple re-
use of the sensor allowing us to monitor cleavage kinetics rather than a single end-point 
measurement or to repeat multiple assays on the same flow cell compatible with inhibitor-
screening applications.  
 
5. Conclusions 
In conclusion this new biosensor method provides a simple, rapid and highly sensitive in vitro 
assay for the enzymatic activity of BoNT/A. SPR biosensors can operate in various media 
(Ferracci et al., 2011) and the presence of BoNT/A could be detected in liquid foods using 
the method proposed. Alternatively the biosensor could be directly connected to a supply of 
drinking water and operate automatically to continuously monitor the presence of BoNT/A by 
repeatedly injecting the specific mAb at fixed times. In the future the method could be 
extended to detect all BoNTs that affect humans, providing antibodies that specifically 
recognize cleaved-substrates can be generated. 
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LEGENDS TO FIGURES 
 
Fig. 1: Characterization of monoclonal antibodies designed to recognize the product 
of SNAP-25 cleavage by botulinum neurotoxin A.  
 a) A rat brain membrane fraction (Marconi et al., 2008) was incubated in the presence or 
absence of 10 nM BoNT/A.  Western blots of membranes were stained with 5 µg/ml of six 
mAbs raised against the 191-197 peptide of SNAP-25. In all cases the major immunoreactive 
bands correspond to the 1-197 fragment of SNAP-25 generated by BoNT/A endoprotease 
activity. Immunoreactivity was not detected in samples untreated by BoNT/A. 
 b) mAb10F12 was immobilized on the active flow cell of a Biacore 3000 apparatus and an 
irrelevant mAb on a control flow cell. Plasma membrane-derived vesicles (Marconi et al. 
2008) pre-treated with BoNT/A (10 nM) were injected in the absence (upper trace) or 
presence (lower trace) of an excess of SNAP-25 191-197 peptide (1 µM).  
Fig. 2: Assay for the endoprotease activity of botulinum neurotoxin A: general 
principle. 
 A sample containing BoNT/A was injected 300 sec over the SNAP-25 sensorchip. The 
deflection to approximately 600 RU and complete return to baseline reflects the change in 
refractive index during sample injection, irrespective of the presence (red trace) or absence 
(black trace) of BoNT/A (400 fM). MAb10F12 was then injected to detect epitopes generated 
by BoNT/A activity. The difference between red and black traces) corresponds to specific 
mAb binding, and indicates the number of neo-epitopes produced, which is directly related to 
BoNT/A activity. Each trace represents a sensorgram monitored in the single flow-cell of a 
Biacore sensor chip.  
Fig. 3: Botulinum neurotoxin A: assay specificity and kinetics. 
 a) Samples containing BoNT/A (1 pM), BoNT/B, BoNT/C, BoNT/E (all at 1 nM) or without 
BoNT (Cont.) were diluted in cleavage buffer and injected for 10 min over a SNAP-25 
sensorchip. SNAP-25 cleavage was detected by injection of mAb10F12 (± SD, n= 3 mAb 
injections). Results are representative of 3 independent experiments. b) Seven successive 
injections of BoNT/A (200 fM) over immobilized SNAP-25 for a duration of 5 min. After each 
injection of toxin, mAb10F12 was injected and the amount of cleaved SNAP-25 measured 10 
sec after the end of injection plotted in c).  
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Fig. 4: Rapid SPR detection of botulinum neurotoxin A at the mouse bioassay 
threshold. 
Cleavage buffer in the presence or absence of 55 fM BoNT/A (1 LD50/ml) was injected over a 
SNAP-25 sensorchip (Biacore T200) for 5 minutes and cleavage products immediately 
detected using mAb10F12. Traces represent a typical experiment with superimposed signals 
generated by 3 injections of mAb10F12. Experiments in the absence of BoNT/A yielded a 
mean of -0.7 ± 0.4 RU (n = 7 independent experiments) and a LOD of 0.5 RU (dashed line). 
Fig. 5: Multispot SPR analysis of botulinum neurotoxin A activity.  
(a) Six samples containing the indicated concentrations of BoNT/A were injected in parallel 
for 15 min and then cleaved SNAP-25 was measured from mAb10F12 binding (n=3). This 
procedure was then repeated 3 times to reach a cleavage time of 60 min. (b) Three 
superimposed sensorgrams at 0.1, 0.3 and 1 LD50/ml  BoNT/A at the final 60 min time point 
in (a). (c) as in (a) with a lower BoNT/A concentration range and a single 5 h injection. (d) as 
in (b) with a lower BoNT/A concentration range and a single 5 h injection. Dashed lines in (a) 
and (c) denote the mean background level from 3 independent experiments plus 3 SD. The 
figure is representative of 3 independent experiments (error bars which are often smaller 
than data points represent SD calculated from 3 mAb injections).  
 
Supplemental Data Legends 
Fig. S1: Detection of SNAP-25 cleaved by botulinum neurotoxin A in cultured 
neurons.  
Cultured rat hippocampal neurons were prepared as described (Ferracci et al., 2011). Cells 
at 15 days in vitro were either untreated (control) or exposed to BoNT/A (1 nM) for 3 hours. 
Cells were then fixed for immunochemistry. SNAP-25 cleavage was detected using 
mAb10F12.  Asterisk indicates soma localization. Scale bar = 20 m.  
 
Fig. S2: Influence of flow rate on protease activity.  
BoNT/A (100 fM) was injected over surface-bound SNAP-25 (Biacore  3000) for 5 minutes at 
flow rates of 1, 5 or 25 µl/ml, followed by injection of mAb10F12. Representative of 3 
independent experiments. 
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Fig. S3: Kinetics of botulinum neurotoxin A using a multispot biosensor. 
Six samples containing the indicated concentrations of BoNT/A were injected for 15 min and 
then cleaved SNAP-25 was measured from mAb10F12 binding (n=3). This procedure was 
then repeated 3 times at each concentration, ie. a total of 4 BoNT/A injections over 1 hour. 
Error bars are not visible. Representative of 3 independent experiments. 
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